Nifekalant
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration |
IV |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | 130636-43-0 ![]() |
PubChem (CID) | 4486 |
ChemSpider | 4331 |
UNII | 5VZ7GZM43E ![]() |
Chemical and physical data | |
Formula | C19H27N5O5 |
Molar mass | 405.44 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(verify) |
Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.[1] It has the brand name Shinbit.
References[edit]
- ^ Oyabe A, Sano H (February 2002). "Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug". Nippon Yakurigaku Zasshi. 119 (2): 103–9. doi:10.1254/fpj.119.103. PMID 11862758.
![]() |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |